Motor cortex electric stimulation for the treatment of neuropathic pain

Walter J. Fagundes-Pereyra, Manoel Jacobsen Teixeira, Nicolas Reyns, Gustavo Touzet, Sérgio Dantas, Emmanuelle Lauureau, Serge Blond

ABSTRACT
Objective: Motor cortex stimulation (MCS) is considered to be an effective treatment for chronic neuropathic pain. The aim of the present study was to assess the efficacy of MCS for treating neuropathic pain.

Method: 27 patients with chronic neuropathic pain were operated. Electrodes were implanted with the use of an stereotactic frame. Electrophysiological evaluations (motor stimulation and somatosensory evoked potentials) were performed, with guidance by means of three-dimensional reconstruction of magnetic resonance images of the brain. 10 patients (37%) presented central neuropathic pain (post-stroke pain) and 17 others (63%) presented peripheral neuropathic pain (brachial plexus avulsion, phantom limb pain or trigeminal pain).

Results: In 15 patients (57.7%) the pain relief was 50% or more; while in ten patients (38.5%), more than 60% of the original pain was relieved. No differences were found in relation to central and peripheral neuropathic pain (p=0.90), pain location (p=0.81), presence of motor deficit (p=0.28) and pain duration (p=0.72). No major complications were observed.

Conclusion: MCS was efficient for treating patients presenting chronic central or peripheral neuropathic pain.

Key words: electric motor cortex stimulation, neuropathic pain, central pain, peripheral pain, treatment.

Estimulação elétrica do córtex motor no tratamento da dor neuropática

RESUMO
Objetivo: A estimulação do córtex motor (ECM) é método considerado eficaz no tratamento da dor neuropática crônica rebelde. O presente estudo avaliou a eficácia da ECM no tratamento de pacientes portadores de dor neuropática crônica.

Método: 27 doentes foram avaliados; 10 (37,0%) apresentavam dor neuropática de origem central, enquanto 17 (63,0%), dor neuropática periférica. Avulsão de raízes do plexo braquial, dor no membro fantasma, dor decorrente de doença cerebrovascular isquêmica ou hemorrágica ou neuropatia trigeminal foram as causas mais frequentes da dor. Os doentes foram operados com uso da técnica de localização estereotáctica do córtex motor associadamente a estudo eletroneurofisiológico (estimulação motora e potencial evocado somatosensitivo) ou ainda com uso de imagens de ressonância magnética do encéfalo reconstruídas tridimensionalmente.

Resultados: O alívio da dor foi igual ou superior a 50% em 15 doentes (57,7%), sendo em 10 (38,5%), superior a 60%. Não houve diferença nos resultados quanto a origem central ou periférica (p=0,90) da dor, localização da dor (p=0,81), ocorrência ou não de déficit motor (p=0,28) e duração da sintomatologia (p=0,72). Não foram observadas complicações graves.

Conclusão: A estimulação do córtex motor foi útil no tratamento da dor neuropática crônica rebelde tanto de origem central como periférica.

Palavras-chave: estimulação elétrica do córtex motor, dor neuropática, dor central, dor periférica, tratamento.
Neuropathic pain is one of the most difficult and worst conditions to treat in clinical practice\(^1\,^2\). Electrical stimulation at different sites in the central nervous system has been shown to induce pain relief, and is now considered to be a viable form of therapy for chronic deafferentation pain\(^2\,^3\).

In 1988, Namba and Nishimoto initially proposed motor cortex stimulation (MCS)\(^4\). In 1991, Tsubokawa et al. introduced epidural MCS as an alternative type of treatment for patients with central deafferentation pain\(^5\). These authors showed that MCS inhibited thalamic burst activity. They treated seven patients presenting thalamic pain by means of epidural MCS with satisfactory pain control in all cases, without major complications\(^5\). Meyerson et al. further extended the indications for MCS by reporting pain relief in relation to trigeminal neuropathic pain\(^6\). Following these examples, many authors have used this technique to treat neuropathic pain from different origins\(^7\,^8\). Syndromes that have been treated by MCS include anesthesia dolorosa and other forms of trigeminal deafferentation pain, central pain secondary to stroke or spinal cord injury, postherpetic neuralgia, peripheral deafferentation pain syndromes such as plexus avulsion, sciatic nerve injury, phantom limb pain, stump pain, complex regional pain syndrome and even glosopharyngeal neuralgia\(^7\,^8\).

Despite an increasing number of indications and procedures over the last few years, many questions remain, concerning the mechanisms of action, indications, predictive factors, implantation strategies and further technical matters in MCS therapy\(^11\).

We report our experience from managing patients with chronic neuropathic pain that was refractory to different types of therapy in a current series of twenty-seven cases treated by means of epidural MCS.

**Table 1.** Demographic data on the patients.

<table>
<thead>
<tr>
<th>Patient number</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Pain origin</th>
<th>Pain location</th>
<th>Vas</th>
<th>Pain duration (months)</th>
<th>Allodynea</th>
<th>Motor deficit</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>52</td>
<td>Stroke</td>
<td>Upper limb</td>
<td>9</td>
<td>48</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>37</td>
<td>Brachial plexus lesion</td>
<td>Upper limb</td>
<td>8</td>
<td>48</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>63</td>
<td>Thalamic hemorrhage</td>
<td>Upper limb</td>
<td>8</td>
<td>60</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>51</td>
<td>Brain injury</td>
<td>Face</td>
<td>10</td>
<td>72</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>62</td>
<td>Brachial plexus lesion</td>
<td>Upper limb</td>
<td>10</td>
<td>24</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>34</td>
<td>Brachial plexus lesion</td>
<td>Upper limb</td>
<td>5</td>
<td>75</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>59</td>
<td>Multiple sclerosis</td>
<td>Face</td>
<td>9</td>
<td>120</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>64</td>
<td>Stroke</td>
<td>Upper limb</td>
<td>8</td>
<td>17</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>40</td>
<td>Brain tumor</td>
<td>Face</td>
<td>10</td>
<td>72</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>28</td>
<td>Brachial plexus lesion</td>
<td>Upper limb</td>
<td>8</td>
<td>41</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>53</td>
<td>Brachial plexus lesion</td>
<td>Upper limb</td>
<td>7</td>
<td>30</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>31</td>
<td>Phantom limb</td>
<td>Upper limb</td>
<td>6</td>
<td>162</td>
<td>None</td>
<td>Amputated</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>45</td>
<td>Brain injury</td>
<td>Face</td>
<td>10</td>
<td>36</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>39</td>
<td>Brachial plexus lesion</td>
<td>Upper limb</td>
<td>8</td>
<td>72</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>67</td>
<td>Trigeminal neuropathic pain</td>
<td>Face</td>
<td>7</td>
<td>84</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>38</td>
<td>Brachial plexus lesion</td>
<td>Upper limb</td>
<td>8</td>
<td>36</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>17</td>
<td>M</td>
<td>33</td>
<td>Brachial plexus lesion</td>
<td>Upper limb</td>
<td>9</td>
<td>15</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>51</td>
<td>Peripheral nerve injury</td>
<td>Upper limb</td>
<td>8</td>
<td>108</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>19</td>
<td>M</td>
<td>35</td>
<td>Stroke</td>
<td>Face</td>
<td>7</td>
<td>24</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>20</td>
<td>F</td>
<td>60</td>
<td>Phantom limb</td>
<td>Lower limb</td>
<td>6</td>
<td>252</td>
<td>None</td>
<td>Amputated</td>
</tr>
<tr>
<td>21</td>
<td>M</td>
<td>41</td>
<td>Brachial plexus lesion</td>
<td>Upper limb</td>
<td>5</td>
<td>57</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>22</td>
<td>M</td>
<td>56</td>
<td>Brachial plexus lesion</td>
<td>Upper limb</td>
<td>8</td>
<td>384</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>23</td>
<td>M</td>
<td>49</td>
<td>Phantom limb</td>
<td>Upper limb</td>
<td>9</td>
<td>348</td>
<td>None</td>
<td>Amputated</td>
</tr>
<tr>
<td>24</td>
<td>M</td>
<td>66</td>
<td>Thalamic hemorrhage</td>
<td>Upper limb</td>
<td>7</td>
<td>60</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>25</td>
<td>M</td>
<td>31</td>
<td>Brachial plexus lesion</td>
<td>Upper limb</td>
<td>6</td>
<td>30</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>26</td>
<td>F</td>
<td>28</td>
<td>Spine cord injury</td>
<td>Upper limb</td>
<td>7</td>
<td>63</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>27</td>
<td>M</td>
<td>50</td>
<td>Brachial plexus lesion</td>
<td>Upper limb</td>
<td>7</td>
<td>360</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

VAS: visual analog scale.
METHOD

Patient population

Twenty-seven patients with chronic central or peripheral neuropathic pain were considered eligible for MCS at Lille University Hospital Center between 1994 and 2002. A summary of the patient data is presented in Table 1. There were 22 males (81.5%) and 5 females (18.5%), aged 28 to 67 years (average of 46.8±12.5 years). Ten patients (37.0%) suffered from central neuropathic pain while 17 others (63.0%) suffered from peripheral neuropathic pain, from different origins. The mean follow-up was 29.1 (±24.6) months (ranging from 7 to 101 months).

All the patients had been treated with different medications, including anticonvulsants, antidepressants, anti-inflammatory agents and even opioid drugs, in various combinations. Four patients had previously been treated by means of drezotomy, three by means of spinal cord stimulation, eleven by means of transcutaneous electrical neurostimulation (TENS), whereas thalamic stimulation was attempted on one patient. All of these approaches failed to sufficiently alleviate the patients’ pain.

Electroneurophysiological and imaging studies and psychological assessment were performed preoperatively on all the patients. Patients presenting either severe depressive or neurotic tendencies were not candidates for MCS.

Pain assessment

The pain level and characteristics of each patient were assessed by a multidisciplinary group at the Pain Clinic affiliated to our service. Each patient was asked to specify the pain intensity according to a visual analog scale (VAS) and by answering a pain questionnaire (McGill questionnaire adapted to French). The effects of stimulation were classified into four categories

In the subsequent 12 patients, after induction of general anesthesia, a rectilinear incision was performed, centered over the central sulcus, in accordance with guidance imaging (Fig 1). This was followed by rectangular craniotomy overlying the sensory-motor cortex, exposing the dura.

All the patients underwent implantation of a quadrripolar stimulation lead with round 5mm electrodes each
separated by 5 mm (Resume™, Medtronic, Inc., Minneapolis, Minnesota, USA). Once the appropriate location was determined based on the guidance imaging system, electrophysiological tests were performed (wave inversion N20-P20) (Fig 2) and motor evoked potentials. The four-electrode array was sutured to the overlying dura of the motor cortex with four stitches, in a perpendicular position based on central sulcus orientation, in a parietal-to-frontal orientation (Fig 3). The free electrode was connected to the extension lead, which was tunneled to a subcutaneous subclavicular pocket, to be connected to a pulse generator (Itrel™, Medtronic, Inc.), by means of a one-stage procedure.

Postoperative care
A skull radiograph was performed to confirm the position of the four-electrode array (Fig 4). We used a programmer (Medtronic, 7432) to generate and adjust the stimuli for different parameters by means of telemetry. Pairs of contacts were used for bipolar stimulation. For monopolar stimulation, one contact over the cortex became the anode (or cathode) while the opposite contact was the pulse generator.

Statistical analysis
Pearson's chi-square ($\chi^2$) test was used for parametric values and Student's t test for non-parametric values. The analysis was performed using the Epi-Info 2000™ software (version 6.0, Centers for Disease Control, Atlanta, USA) and Statistica™ software (version 6.0, Statsoft Inc, USA). Fisher's exact test correction was used when the values were less than five.

RESULTS
Pain relief
Among the 26 patients analyzed, pain relief greater than or equal to 50% was observed in 15 patients (57.7%). In relation to the criteria established, 10 patients (38.5%) achieved satisfactory relief (good or excellent). In four patients (15.3%), gradual improvement of pain occurred over the first twelve months following the procedure, and the results became satisfactory. In five patients (19.2%), although satisfactory initial relief was observed, the improvement gradually reduced over subsequent months (Fig 5). In one of the patients, one year after the implantation, the pulse generator was turned off; therefore, the initial pain relief was not sustained.

The difference in the mean VAS scores between the preoperative period (before MCS) and the end of the follow-up period was statistically significant (p<0.000001) (Table 2 and Fig 6).

In four patients, the pain control gradually increased over a period of several months, becoming satisfactory in
some of them. However, in five patients, pain control was initially achieved, but the effect progressively faded away over a period of several months and, in some of them, the pain control became unsatisfactory.

One patient did not benefit from MCS, and the pulse generator was stopped after one year. Surprisingly, one patient showed an improvement in associated hand dystonia.

No differences in relation to age (p=0.71), gender (p=0.69), origin of the lesions (central or peripheral) (p=0.90), area of the pain (p=0.81), presence of motor deficit (p=0.28) or duration of pain (p=0.72) were observed between the patients with satisfactory pain control and the patients without such control.

In 11 patients (42.3%), a reduction in the amount of analgesic medication intake was possible.

**Stimulation parameters**

Stimulation was performed at a pulse width of 45 to 60 µs initially, reaching a maximum of 60 to 210 µs at the end. The frequency ranged from 45 to 60 Hz initially, and was from 45 to 130 Hz at the last follow-up assessment. The amplitude initially ranged from 2 to 4 V (2.9±0.57), and was from 2 to 5.3 V (4±0.8) at the end. Monopolar stimulation was used for 7 patients (26.9%), and bipolar stimulation was used for 19 (73.1%). The active electrodes were defined by perioperative neurophysiological evaluations and were adapted postoperatively in accordance with the patient’s response. Bipolar stimulation was used with the negative pole overlying the motor cortex and the positive pole over the sensory cortex. The stimulation mode was variable, in accordance with the patient’s response, and could even change for the same patient several times.

**Morbidity**

Stimulation at high amplitude levels during in-patient titration resulted in focal epileptic seizures in two patients. One patient developed scar dehiscence after pulse generator replacement, because of battery arrest. In two patients, infection of the stimulator pocket was observed, and in one of them, the pulse generator was removed and a new one was implanted in the opposite side. In the second case, antibiotic therapy was sufficient and no replacement was necessary.

**DISCUSSION**

The 46.1% of the patients with more than 50% pain relief and the 69.2% with more than 40% pain relief observed in this study are similar to the rates obtained in other studies, which observed that 50% of the patients treated with MSC had over 50% pain relief. In a critical review of the literature, Fontaine et al. noticed that a good response to MCS (pain relief ≥40-50%) was observed in around 55% of the patients who underwent surgery, and in 45% of the 152 patients with a postoperative follow-up ≥1 year. Carroll et al. reported that this rate was encouraging in this difficult group of patients, who have usually failed to respond to other types of treatment.

If the three-category classification used by Nguyen et al. and Lefaucher et al. (good; VAS score reduction by 70-100%; satisfactory: reduction by 40-69%; and poor: reduction by <40%) had been applied to our data, we would have observed that 69.2% of the results were good and satisfactory.

In another review, Smith et al. showed that a positive response was achieved in 44 to 100% of MCS-treated patients.

It seems relevant to point out that some patients who were not considered to have a satisfactory response, i.e. among whom the pain relief was only 30-40%, were intolerant of MCS interruption. This denotes that even if the response is far from what would be desirable, it should
not be disregarded in this particular group of patients suffering from a terrible type of pain, among whom almost all the current therapies had previously been attempted without success. Considering these rates in association with other types of therapy, if an intolerable pain can be transformed into an acceptable pain, this may be significant for the patient’s quality of life.

In the beginning of this series, we performed electrode placement through a burr hole. However, as suggested by some authors, we decided to perform craniotomy. The use of craniotomy allows for more extensive electrophysiological exploration. Electrode introduction through a burr hole limits the exploration. For these reasons, we opted for craniotomy for the last 12 cases of the present series. Another refinement to our technique was the introduction of the guidance imaging system. Accurate localization of the motor cortex and precise electrode placement according to the painful areas is essential in obtaining good results.

Predicting pain relief from MCS is a major clinical problem. Barbiturate sensitivity and opioid insensitivity have been suggested as possible predictors of the response. Transcranial magnetic stimulation may be another useful tool for this purpose. The motor response in the painful area may also be useful. However, as pointed out by Smith et al., the results from such tests are not a guarantee of a successful outcome. Therefore, we did not routinely perform any prediction-specific assessments.

Although an intact somatosensory system is not essential for successful treatment, the presence of an intact corticospinal tract with muscle twitching has been considered to be a prior requirement for sufficient analgesia in the respective areas of stimulation. Katayama et al. observed that pain relief was satisfactory in 73% of the patients with mild or absent motor weakness. When motor weakness was present, ranging from moderate to severe, only 15% of the 13 patients benefited therapeutically from it. When motor contractions could not be induced, pain relief was achieved in only 9% of the patients. Despite these reports, the motor response could not be obtained in 11 patients with plexus avulsion in our series but, nevertheless, excellent or good pain relief was observed in three of them (27%).

We observed a decrease in the effect from MCS in some patients after long-term follow-ups, just as other centers have done. Tsukbokawa et al. showed that a tissue reaction in the dura may increase the impedance of the stimulation site. Sudden increases in pain have always either been associated with lead fractures or been provoked by the fact that the pulse generator was switched off.

Surgery-related epidural hematoma, subdural effusion, infection and dehiscence of the stimulator pocket have been reported. Other effects directly attributed to MCS have included epileptic seizures, aphasia, dysphasia, upper extremity fatigue, burning sensations in the area of stimulation, feeling of a supernumerary arm and even dystonia. Chronic seizures following MCS have not been observed.

In one patient in our series, hand dystonia improvement was observed, as was also observed by Franzini et al. Postoperative titration of stimulation parameters should be performed for each individual patient, since the response is usually variable. Different stimulation patterns were attempted until adequate pain relief was achieved but, unfortunately, in some cases no satisfactory pain control was observed.

MCS is a non-destructive therapeutic technique and should be considered before undertaking central neuroablative procedures, when treating chronic neuropathic pain.

In conclusion, MCS is a non-destructive, adjustable and reversible therapeutic technique that is efficient for treating patients presenting chronic central or peripheral neuropathic pain syndromes that are refractory to other types of treatment, even though its mechanisms of effect are still not well established.

ACKNOWLEDGEMENTS – We thank the staff of the Pain Unit of the Department of Neurosurgery, Roger Salengro Hospital of Lille University, for clinical support.

REFERENCES